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Background: The efficacy of medical treatment among obese men with lower urinary tract symptoms (LUTS) has
been less clear, especially regarding the improvement of QoL. We aimed to investigate the difference in efficacy
and consequent satisfaction of life quality after medical treatment of male LUTS according to obesity.
Methods: An 8-week prospective study was performed for a total of 140 patients >50 years old with International
Prostate Symptom Scores (IPSS) > 12 points and prostate volume > 20 mL. Obesity was determined by either body
mass index (BMI) or waist circumference (WC). Patients were divided into 2 groups according to BMI or WC. Patients
received tamsulosin at a dose of 0.4 mg daily for 8 weeks. The changes from baseline in the IPSS, maximal urinary
flow rate (Qmax), post-void residual volume, questionnaire of quality of life (QoL), and King’s Health Questionnaire
(KHQ) were analyzed.
Results: Of the 150 enrolled patients, 96 completed the study. Seventy-five patients (78.1%) had BMI ≥ 23 kg/m2,
and 24 (25.0%) had WC > 90 cm. Overall, the IPSS, IPSS QoL, and total KHQ showed significant improvement. Obese
(BMI ≥ 23 kg/m2) and non-obese (BMI < 23 kg/m2) both showed improvement of the IPSS and IPSS QoL scores,
but only the obese (BMI ≥ 23 kg/m2) group showed improvement of the total KHQ score (P < 0.001 vs. P = 0.55).
Only the obese (WC > 90 cm) group showed improvement of the IPSS and total KHQ scores (P < 0.001).
Conclusions: Our preliminary study showed the different efficacy of an alpha-blocker for improvement of LUTS
and life quality according to obesity. Obese patients, defined by BMI or WC, showed the tendency toward a more
favorable improvement of LUTS and life quality.
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Benign prostatic hyperplasia (BPH)/lower urinary tract
symptoms (LUTS) is a common disease entity in older
men and has a negative impact on quality of life (QoL)
[1-3]. Obesity is also a common condition in older males
and is related to LUTS [1,3]. As in Western countries,
Korean men have a high prevalence of symptomatic
BPH as they age, with a prevalence of 10.6%–31% in
men > 50 years old [2,4]. Several studies have reported a
significant relationship between LUTS and obesity [3,5,6].
Considering the objective evidence of a negative effect of
both LUTS [7-13] and obesity [14] on QoL, LUTS plus
obesity may result in a greater deterioration of QoL.
Among the alpha blockers, tamsulosin is one of the
most commonly recommended because of its efficacy,
safety, and tolerability [15]. The King’s Health Question-
naire (KHQ) is a validated tool to measure the QoL in
patients with LUTS [9]. Although the KHQ was devel-
oped originally for female urge incontinence, validity has
been proven in studies that dealt with LUTS and health-
related quality of life (HRQoL) in both sexes [9,16-19].
To date, efficacy of medical treatment among obese men
with LUTS has been less clear, especially regarding the im-
provement of QoL within specific domains. Recently, Lee
et al. [14] reported that alpha-blockers have a greater effi-
cacy in improvement of LUTS when used in obese men.
The main presumed hypothesis for this difference is that
obese men have a greater level of sympathetic activity,
which is suspected to be sensitive to alpha-blockers [20,21].
The main purpose of this preliminary study is to inves-
tigate the improvement of LUTS and QoL in different
groups (obese and non-obese).
Methods
Study design
An eight-week prospective study was conducted between
March 2010 and May 2011. The study was approved by
the institutional review board of Soonchunhyang University
Hospital.
At the initial visit, anthropometric parameters were
evaluated, including weight, height, and waist circumfer-
ence. Additional parameters measured included urinalysis,
serum prostate-specific antigen [22], maximal urinary flow
rate (Qmax), and post-void residual volume (PVR). Trans-
rectal ultrasonography was also performed. At the initial
and final visits, the International Prostate Symptom Score
(IPSS) and KHQ were measured.
BMI was calculated as the body weight in kilograms
divided by the square of the height in meters. After the
first evaluation, eligible patients were treated with tam-
sulosin at a dose of 0.4 mg for 8 weeks. At each visit,
adverse events were recorded.
Serum PSA tests were performed using the automated
chemiluminescent microparticle immunoassay analyzerArchitect i2000 (Abbott Diagnostic Laboratories, Abbott
Park, IL, USA). The prostate was measured in three
dimensions by transrectal ultrasonography using an
8.0-MHz rectal probe (GE Healthcare, LOGIQ P6-PRO,
Little Chalfont, UK), and prostate volume (PV) was es-
timated using a modification of the prolate ellipsoid
formula and recorded in cm3 (0.523 [length (cm) × width
(cm) × height (cm)]).
Acquisition of questionnaire data was performed with
face-to-face interviews conducted by one investigator with
all study participants using a structured questionnaire.
The severity of LUTS was measured using the IPSS, which
is based on the American Urological Association [23]
symptom index with one additional question on QoL, and
is the most widely used objective assessment of LUTS.
The KHQ consists of 8 categories, including general
health perceptions, impact on life, role limitations, physical/
social limitation, personal relationships, emotions, sleep/
energy, and incontinence severity measures. The KHQ has
been validated in a Korean version [24].
Subjects
A total of 150 patients who visited the Department of
Urology at Soonchunhyang University and provided in-
formed consent were included in this study. Inclusion
criteria were male ≥ 40 years of age, no history of prior
treatment of BPH/LUTS, total IPSS ≥ 8, prostate vol-
ume > 20 mL as determined by transrectal ultrasound,
no relevant medical history, and underlying comorbidities.
Exclusion criteria were history of neurogenic bladder dys-
function, history of prostate or bladder cancer, treatment
history of acute or chronic urinary retention within
the previous 3 months, treatment history of acute or
chronic prostatitis within the previous 3 months, PSA
levels > 0.10 ng/mL, and history of urinary tract infection
or bladder stones.
All patients were divided into 2 groups, non-obese
(BMI < 23 kg/m2) and obese (BMI ≥ 23 kg/m2), according
to the Asia-Pacific obesity criteria [25]. For additional ana-
lysis, we also categorized patients into 2 groups based on
waist circumference (WC), normal waist (≤90 cm) and
central obesity (>90 cm).
Power calculation
Sample size was not calculated because its being a pre-
liminary study.
Statistical analysis
The primary outcome measurement was the degree of
change of KHQ in the two groups, and secondary out-
come measurement was the degree of change of IPSS in
the two groups. All data are presented as mean ± SD.
Statistical analysis was performed using SPSS (version
21.0; Chicago, IL, USA). Changes from baseline in total
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Wilcoxon signed-rank test. A P value < 0.05 was consid-
ered significant.
Results
Of the 140 enrolled patients, 96 completed the study.
Fifty four patients discontinued the trial. Of these, 22
were lost to follow-up, 14 refused to complete the final
questionnaires, and 18 patients discontinued the medica-
tion because of low efficacy (9 patients) or adverse events
(9 patients) (Figure 1).
The basic characteristics, including age, PSA, PV,
Qmax, total IPSS, and KHQ questionnaire are described
in Table 1. Between the obese group (BMI ≥ 23 kg/m2)
and non-obese group (BMI < 23 kg/m2), no significant
difference occurred among the variables. Between the
central obesity group (WC > 90 cm) and non-central
obesity group (WC ≤ 90 cm), no significant difference
occurred among the variables except age.
After 8 weeks treatment with tamsulosin, overall
improvement was seen in the total IPSS and IPSS
QoL (P < 0.001) (Table 2). Total KHQ scores also im-
proved after treatment (P < 0.001). Among the domains,
general health, impact on life, role limitations, physical
limitation, emotions, sleep/energy, and incontinence se-
verity were improved or significantly improved. However,
social limitation and personal relationships did not show
improvement after treatment (Table 2).Figure 1 Flow chart of enrolled patients.In subgroup analysis, the non-obese group showed
no improvement in total KHQ (P = 0.055) (Table 3).
Among the KHQ domains, the obese group showed
improvement only in general health (P = 0.025), impact
on life (P = 0.020), and emotions (P = 0.047). The obese
group showed improvement in total KHQ (P < 0.001)
(Table 3). Among the KHQ domains, the obese group
showed improvement in general health (P < 0.001), impact
on life (P < 0.001), role limitations (P = 0.001), physical
limitation (P < 0.001), and emotions (P < 0.001). The com-
parison of improvement of IPSS and KHQ revealed that
obesity group showed significant greater improvement in
total IPSS, physical limitation, and sleep/energy (Table 4).
In other subgroup analysis, the non-central obesity
group showed no improvement in total IPSS, IPSS QoL,
and total KHQ (Table 4). Among the KHQ domains, the
non-central obesity group showed improvement only in
general health (P = 0.020) and impact on life (P = 0.032).
The central obesity group showed improvement in total
IPSS, IPSS QoL, and total KHQ (Table 5). Among the
KHQ domains, the central obesity group showed im-
provement in general health P < 0.001), impact on life
(P < 0.001), role limitations (P < 0.001), physical limitation
(P = 0.002), personal relationships (P = 0.029), emotions
(P < 0.001), and sleep/energy (P = 0.024). The comparison
of improvement of IPSS and KHQ revealed that central
obesity group showed significant greater improvement in
total IPSS, impact of life, and sleep/energy (Table 5).
Table 1 Basic characteristics of participants
BMI < 23 BMI ≥ 23 P value WC ≤ 90 WC > 90 P value
No 21 75 72 24
Age 61.25±9.80 61.48±7.09 0.982 60.58±7.60 64.20±7.54 0.045
PSA 2.12± 2.04± 0.231 2.13± 1.98± 0.312
PV 31.12±10.14 34.23±8.71 0.042 32.31±9.81 33.23±10.21 0.218
Qmax 12.32±2.21 13.25±1.75 0.134 11.46±1.89 13.33±2.34 0.185
IPSS questionnaire
Total IPSS 14.90±7.58 13.41±6.79 0.388 15.00±7.57 13.31±6.74 0.308
IPSS QoL 3.47±1.21 3.54±1.22 0.830 3.56±1.40 3.51±1.15 0.864
KHQ questionnaire
General health 41.66±18.25 47.66±23.67 0.286 47.91±26.49 45.83±21.39 0.698
Impact on life 53.91±30.65 58.60±30.40 0.534 58.27±28.20 57.35±31.22 0.898
Role limitations 25.29±33.45 28.77±31.98 0.664 33.20±37.91 26.28±30.10 0.364
Physical limitation 29.24±31.45 27.44±30.08 0.811 33.20±34.26 26.05±28.79 0.318
Social limitation 22.19±31.81 16.71±25.48 0.411 18.03±24.83 17.87±27.59 0.980
Personal relationships 21.71±37.96 25.39±32.24 0.724 24.90±35.34 24.55±32.84 0.972
Emotions 25.90±31.06 27.52±25.83 0.808 31.91±29.15 25.59±26.12 0.321
Sleep/Energy 26.08±29.49 21.02±26.64 0.454 18.67±24.13 23.28±28.22 0.475
Incontinence 14.14±27.47 9.85±14.73 0.343 16.50±21.31 8.89±16.76 0.076
Total KHQ 251.88±223.71 254.88±171.03 0.947 274.31±198.90 247.53±178.02 0.537
Kim et al. BMC Urology 2014, 14:60 Page 4 of 8
http://www.biomedcentral.com/1471-2490/14/60Adverse events were reported in 9 patients (6.0%) and
included dizziness (3.3%), postural hypotension (1.3%),
and gastric discomfort (1.3%).
Discussion
When obese patients with BPH have LUTS, a larger
prostate is presumed to be one of the causes. TheTable 2 Differences in IPSS and KHQ before and after treatme
Mean difference SD
IPSS
IPSS questionnaire 3.521 6.76
QoL 1.011 1.48
KHQ
General health 13.281 25.38
Impact on life 18.417 32.51
Role limitations 10.302 26.95
Physical limitation 9.490 26.41
Social limitation 3.323 24.41




Total KHQ 76.167 144.3prostate grows faster in obese than in non-obese patients
[26-28].
Many clinical studies have focused on prostate size or
PSA in obese patients, but few studies have focused on
the treatment outcome, including QoL, in obese patients.
Although several studies have used the IPSS-QoL index
to present the treatment outcome in obese patientsnt
95% CI P value
4 2.150 4.891 < 0.001
7 .701 1.321 < 0.001
0 8.139 18.424 < 0.001
3 11.829 25.004 < 0.001
4 4.841 15.764 < 0.001
7 4.137 14.842 0.001
8 −1.625 8.271 0.186
8 −1.365 11.931 0.117
2 5.624 13.689 < 0.001
9 .038 9.225 0.048
1 .145 5.876 0.040
46 46.920 105.414 < 0.001
Table 3 Differences in IPSS and KHQ before and after treatment according to BMI
BMI < 23 BMI ≥ 23
Mean difference SD P value Mean difference SD P value
IPSS questionnaire
Total IPSS 5.571 7.928 .004 2.947 6.341 < 0.001
QoL 1.105 1.243 .001 .986 1.552 < 0.001
KHQ questionnaire
General health 10.714 20.266 .025 14.000 26.712 < 0.001
Impact on life 20.619 37.377 .020 17.800 31.269 < 0.001
Role limitations 9.381 27.006 .127 10.560 27.116 0.001
Physical limitation 3.190 34.945 .680 11.253 23.483 < 0.001
Social limitation 8.429 27.770 .180 1.893 23.400 0.486
Personal relationships 5.556 37.250 .666 5.227 21.101 0.108
Emotions 10.571 22.892 .047 9.400 19.146 < 0.001
Sleep/Energy 7.048 25.488 .220 3.946 21.785 .124
Incontinence 6.524 23.159 .211 2.027 10.357 .094
Total KHQ 79.762 179.641 .055 75.160 134.246 < 0.001
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tionnaire. Rather, it represents the state of generalized
HRQoL in men with LUTS.
The most prominent feature of our study was use of the
KHQ questionnaire, a disease-specific HRQoL instrument
for the evaluation of patients with LUTS, overactive
bladder, and urinary incontinence [9,16-19]. The KHQ
consists of nine domains. Seven of the domains include
multiple questions including role limitations, physical
limitations, social limitations, personal relationships, emo-




Total IPSS 2.667 7.191
QoL .957 1.637
KHQ questionnaire
General health 14.583 28.473
Impact on life 15.292 32.742
Role limitations 8.250 38.649
Physical limitation 8.333 28.448
Social limitation .083 20.581




Total KHQ 52.333 165.817Our study revealed that comparison of improvement
of IPSS QoL according to BMI and WC showed no sig-
nificant difference. However, the comparison of improve-
ment KHQ including impact on life, physical limitation,
impact of life, and sleep/energy showed significant differ-
ence. Although improvement of total KHQ showed no
significant difference, several domains of KHQ showed
significant differences.
Although some controversies exist regarding the rela-
tionship between the severity of LUTS and obesity,
obese patients usually have more severe LUTS thannt according to waist circumference
WC ≥ 90
P value Mean difference SD P value
.082 3.806 6.643 < 0.001
.010 1.029 1.445 < 0.001
.020 12.847 24.464 < 0.001
.032 19.458 32.600 < 0.001
.307 10.986 22.053 < 0.001
.165 9.875 25.904 0.002
.984 4.403 25.610 0.149
.418 8.872 24.369 0.029
.335 11.653 20.147 < 0.001
.630 6.690 24.404 0.024
.251 3.014 14.733 0.087
.136 84.111 136.806 < 0.001
Table 5 Comparison of the differences in IPSS and KHQ according to BMI and waist circumference
BMI < 23 BMI ≥ 23 P value WC ≤ 90 WC > 90 P value
IPSS questionnaire
ΔTotal IPSS 3.37±6.17 6.00±7.66 0.041 2.87±7.18 4.30±6.38 0.028
ΔIPSS QoL 0.96±1.52 1.00±1.22 0.830 0.79±1.79 1.02±1.34 0.231
KHQ questionnaire
ΔGeneral health 10.71±20.26 14.00±26.71 0.286 14.58±28.47 12.84±24.46 0.321
ΔImpact on life 17.76±31.12 20.06±37.19 0.052 15.26±32.53 19.42±32.46 0.028
ΔRole limitations 10.61±27.10 9.48±27.05 0.564 8.30±38.54 11.06±22.11 0.356
ΔPhysical limitation 3.16±35.06 11.28±23.50 0.032 8.30±28.54 9.91±25.93 0.068
ΔSocial limitation 4.20±22.84 3.16±27.08 0.347 4.01±20.62 4.39±25.64 0.780
ΔPersonal relationships 5.71±27.96 5.39±22.24 0.561 5.09±22.05 4.71±28.32 0.814
ΔEmotions 9.47±19.19 10.57±22.87 0.706 10.91±18.41 11.76±20.14 0.415
ΔSleep/Energy 3.98±21.63 7.11±25.48 0.031 3.21±14.61 6.68±24.23 0.035
ΔIncontinence 19.69±24.66 18.35±24.96 0.381 18.43±24.99 19.72±24.64 0.451
ΔTotal KHQ 75.20±134.25 79.87±179.59 0.061 52.47±165.90 84.14±136.77 0.071
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phenomenon are lower testosterone concentrations,
lower serum globulin-binding protein levels, and greater
prostate volumes in obese patients [31], as well as in-
creased estrogen levels and increased free and total
estradiol concentrations [32,33].
Our data demonstrate that the baseline total IPSS
showed no significant difference between the obese and
non-obese groups or central obesity and non-central
obesity groups. This is mainly due to our lower IPSS
inclusion criteria of more than 8 points total on the
IPSS. We lowered the criteria for the IPSS because pa-
tients scoring higher on the IPSS could bias the results
by showing more satisfaction with treatment.
Our data showed a more favorable treatment outcome
in obese patients and those with central obesity. Although
an improvement in the total IPSS was demonstrated in
both obese and non-obese patients, the improvement in
the total IPSS was only demonstrated in patients with
central obesity. Improvement in total KHQ scores was
demonstrated only in obese patients and patients with
central obesity.
Greater estrogen levels in old age and obesity induce
lower testosterone levels and may affect prostate cell
growth [32]. Enlarged adipose tissue can secrete numer-
ous hormones and proteins that influence fat metabolism
[34,35], and leptin stimulates the cellular proliferation of
BPH [36,37].
Besides an enlarged prostate, obese patients have
increased sympathetic tone, which is suspected to be the
main reason alpha blockers could have a greater impact
in obese patients. Increased sympathetic tone can result
in LUTS and subjective voiding complaints [19]. In
particular, abdominal obesity increases the estrogen-to-androgen ratio and may increase sympathetic nervous
system activity, both of which are known to influence the
development of BPH and the severity of LUTS [18]. In
our study, obese patients showed improvement in 5 do-
mains of the KHQ, but central obesity patients showed
improvement in 7 domains of the KHQ. This result
implies that obesity, especially central obesity, which is
regarded as visceral obesity, could impact treatment
outcomes. The main reason for this result is that obes-
ity, and especially visceral adiposity, is closely related to
sympathetic overactivity [38,39]. The whole body nor-
epinephrine spillover rate is known to be quantitatively
linked with waist circumference [17,31], and sympa-
thetic nerve firing rates measured by microneurography
have been reported to be 55% higher in men with vis-
ceral adiposity than in men with only subcutaneous
obesity.
Sympathetic activity is increased in obese men and may
be related to BPH/LUTS by a common link between nor-
epinephrine and alpha-1 adrenoceptors [38,39]. Although
general improvement of LUTS and KHQ were observed
in this study, the obesity and central obesity groups
showed more improvement in the IPSS and KHQ.
This study has several limitations. First, the study design
has a relatively short follow-up period. However, 8 weeks is
sufficient to judge the clinical outcome of alpha blockers.
Moreover, the KHQ is a relatively long questionnaire and
takes a long time to perform, which reduces patient com-
pliance. Although the acquisition of questionnaire was per-
formed by one special interviewer, a lot of patients showed
negative response to the KHQ in our study. The most
common reason for this negative response is that it takes
quite a long time. This is why we did not perform an add-
itional KHQ at 4 weeks. Second, this study has a relatively
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of concomitant medical diseases, the availability of eligible
patients is limited. This was a pilot; a preliminary study,
and subsequent prospective study is needed.
Conclusions
Obese or central obesity patients with LUTS showed a
better health-related quality of life than non-obese or
non-centrally obese patients with LUTS after alpha-adren-
ergic medication. Therefore, alpha-adrenergic medication
can be recommended to obese patients with LUTS prefer-
entially for the improvement of quality of life.
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